# ADR 518 — Enterprise Biotechnology Bio Security Intelligence Platform (P217-S)

## Status

Accepted

## Context

P217-R established bio investment intelligence. P217-S defines Bio Security & Resilience: bio cybersecurity, biological risk intelligence, threat intelligence, resilience engineering and security digital twin — before Bio Future (P217-T).

## Decision

1. SoR remains `biotechnology` / `CAP-PLT-BIO-001` for security *intelligence* — never replace Identity or Audit platforms.
2. Fabric: `meos_bio_security_intelligence_fabric`.
3. API: `/api/v1/biotechnology/bio-security*`.
4. Six security layers; cybersecurity, risk, threat, resilience, KG, and twin platforms.
5. All inference via P214-Z ACL only — `no_module_local_llm`.
6. Human security oversight and zero-trust controls mandatory; never autonomous defense without approval.
7. Twins via P217-G; regulatory via P217-N; sustainability via P217-O; marketplace via P217-P; innovation via P217-Q; investment via P217-R; robotics via P216-Z; quantum via P215-Z.
8. Never replace Core, AI, Quantum, Robotics, Identity, Audit, hospital EMR, LIMS, pharmacy, prior P217 fabrics including Bio Investment.
9. Foundation for P217-T.

## Consequences

Positive: governed security/resilience layer for future bio-civilization phases.  
Negative: threat / twin catalogs must stay aligned as autonomous defense systems deepen under human oversight.

## Alternatives rejected

- Sibling `bio_security` BC owning Identity/Audit or Core capabilities.
- Module-local LLM or autonomous defense without human approval.
- Merging peer SoRs (EMR/LIMS/pharmacy/Identity/Audit) into biotechnology without ACL peers.

## Related

Law: `ENTERPRISE_BIOTECHNOLOGY_BIO_SECURITY.md` · Prior: ADR 499–517 · Next: P217-T
